[{"id":"69c0c3d7-d12e-4846-a87b-98d5f38f2dcd","acronym":"SJDAWN","url":"https://clinicaltrials.gov/study/NCT03434262","created_at":"2021-01-18T16:56:26.116Z","updated_at":"2025-02-25T15:54:00.489Z","phase":"Phase 1","brief_title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","source_id_and_acronym":"NCT03434262 - SJDAWN","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-05-31"},{"id":"a9577f45-e57c-4142-84ae-067eccfe367a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04007744","created_at":"2021-01-18T19:41:36.045Z","updated_at":"2024-07-02T16:35:12.692Z","phase":"Phase 1","brief_title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04007744","lead_sponsor":"Mayo Clinic","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MSI • BCL2 • BCL2L11","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["EGFR • PD-L1 • BRAF • ALK • MSI • BCL2 • BCL2L11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/13/2020","start_date":" 02/13/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-03-26"},{"id":"aa1cebd7-d5ff-467e-9ba4-a573015d172c","acronym":"PersoMed-I","url":"https://clinicaltrials.gov/study/NCT04402073","created_at":"2021-01-18T21:14:10.343Z","updated_at":"2024-07-02T16:35:26.623Z","phase":"Phase 2","brief_title":"Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma","source_id_and_acronym":"NCT04402073 - PersoMed-I","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" TP53 • BRCA2 • MYCN","pipe":" | ","alterations":" TP53 wild-type • MYCN amplification","tags":["TP53 • BRCA2 • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • vincristine • lomustine • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 205","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2023-12-11"},{"id":"e1683f45-f260-4fe6-a1c8-c64aaf27d499","acronym":"EDALINE","url":"https://clinicaltrials.gov/study/NCT02027376","created_at":"2021-01-18T09:17:00.650Z","updated_at":"2025-02-25T15:41:12.890Z","phase":"Phase 1","brief_title":"Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients","source_id_and_acronym":"NCT02027376 - EDALINE","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2023-04-03"},{"id":"2bb7d6c9-0473-46c7-9460-ae9487c6e000","acronym":"","url":"https://clinicaltrials.gov/study/NCT04679480","created_at":"2021-01-19T20:46:22.519Z","updated_at":"2024-07-02T16:36:00.949Z","phase":"Phase 2","brief_title":"Anti-PD1-antibody and Pulsed HHI for Advanced BCC","source_id_and_acronym":"NCT04679480","lead_sponsor":"Reinhard Dummer","biomarkers":" CD8 • PD-1 • CD4 • CD200 • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression","tags":["CD8 • PD-1 • CD4 • CD200 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-04"},{"id":"dcfdfb8d-1bd6-45ea-82d2-226512a2eba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01576666","created_at":"2021-01-18T06:42:34.232Z","updated_at":"2024-07-02T16:36:37.119Z","phase":"Phase 1","brief_title":"Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01576666","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e buparlisib (AN2025) • Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2020-12-19"},{"id":"b0e55042-5c0a-4922-b41d-814b4c0bc249","acronym":"","url":"https://clinicaltrials.gov/study/NCT01456676","created_at":"2022-04-24T08:55:35.467Z","updated_at":"2024-07-02T16:36:37.562Z","phase":"Phase 1","brief_title":"Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy","source_id_and_acronym":"NCT01456676","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2020-12-09"},{"id":"56b9b02a-ad6f-4be1-aa31-c584f083e121","acronym":"","url":"https://clinicaltrials.gov/study/NCT02129101","created_at":"2021-01-18T09:52:18.475Z","updated_at":"2024-07-02T16:36:54.150Z","phase":"Phase 1","brief_title":"Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies","source_id_and_acronym":"NCT02129101","lead_sponsor":"Mayo Clinic","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • decitabine • Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 10/25/2019","study_completion_date":" 10/25/2019","last_update_posted":"2019-10-30"},{"id":"b9a2bdff-ff07-4e10-adff-f14635a883a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02111187","created_at":"2021-01-18T09:45:47.717Z","updated_at":"2024-07-02T16:37:02.137Z","phase":"Phase 1","brief_title":"A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer","source_id_and_acronym":"NCT02111187","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 01/18/2017","primary_completion_date":" 01/18/2017","study_txt":" Completion: 01/18/2017","study_completion_date":" 01/18/2017","last_update_posted":"2019-03-07"},{"id":"f6ad9491-23d0-45b8-b0d6-2485c78b5a5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01529450","created_at":"2021-01-18T06:27:04.150Z","updated_at":"2025-02-25T15:52:35.247Z","phase":"","brief_title":"Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors","source_id_and_acronym":"NCT01529450","lead_sponsor":"Anne Chang","biomarkers":" PTCH1","pipe":"","alterations":" ","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 08/01/2013","study_completion_date":" 08/01/2013","last_update_posted":"2017-01-16"}]